Neurotrauma Reports (Jan 2022)

Pharmaceutical Venous Thrombosis Prophylaxis in Critically Ill Traumatic Brain Injury Patients

  • Jilske A. Huijben,
  • Dana Pisica,
  • Iris Ceyisakar,
  • Nino Stocchetti,
  • Giuseppe Citerio,
  • Andrew I.R. Maas,
  • Ewout W. Steyerberg,
  • David K. Menon,
  • Mathieu van der Jagt,
  • Hester F. Lingsma,
  • Collaboration group,
  • Collaboration group

DOI
https://doi.org/10.1089/NEUR.2021.0037
Journal volume & issue
Vol. 2, no. 1
pp. 4 – 14

Abstract

Read online

The aims of this study are to describe the use of pharmaceutical venous thromboembolism (pVTE) prophylaxis in patients with traumatic brain injury (TBI) in Europe and study the association of pVTE prophylaxis with outcome. We included 2006 patients ?18 years of age admitted to the intensive care unit from the CENTER-TBI study. VTE events were recorded based on clinical symptoms. Variation between 54 centers in pVTE prophylaxis use was assessed with a multi-variate random-effect model and quantified with the median odds ratio (MOR). The association between pVTE prophylaxis and outcome (Glasgow Outcome Scale-Extended at 6 months) was assessed at center level with an instrumental variable analysis and at patient level with a multi-variate proportional odds regression analysis and a propensity-matched analysis. A time-dependent Cox survival regression analysis was conducted to determine the effect of pVTE prophylaxis on survival during hospital stay. The association between VTE prophylaxis and computed tomography (CT) progression was assessed with a logistic regression analysis. Overall, 56 patients (2%) had a VTE during hospital stay. The majority, 1279 patients (64%), received pVTE prophylaxis, with substantial between-center variation (MOR, 2.7; p?<?0.001). A moderate association with improved outcome was found at center level (odds ratio [OR], 1.2 [0.7?2.1]) and patient level (multi-variate adjusted OR, 1.4 [1.1?1.7], and propensity adjusted OR, 1.5 [1.1?2.0]), with similar results in subgroup analyses. Survival was higher with the use of pVTE prophylaxis (p?<?0.001). We found no clear effect on CT progression (OR, 0.9; CI [0.6?1.2]). Overall, practice policies for pVTE prophylaxis vary substantially between European centers, whereas pVTE prophylaxis may contribute to improved outcome. Trial registration number is NCT02210221 at ClinicalTrials.gov, registered on August 6, 2014 (first patient enrollment on December 19, 2014).

Keywords